Tonix Pharmaceuticals-Boca Raton Lunch

6000 Glades Road,Boca Raton FL 33431

10 March, 2022

Description

Come learn about Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and their management team *Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Bear Creek Capital Presents:Tonix Pharmaceuticals Holding Corp. (NASDAQ:  TNXP)The Capital Grille6000 Glades RoadBoca Raton, FL 33431Thursday, March 10, 2022Promptly at 12:00 PM Join Tonix Pharmaceuticals' Co-Founder, President, CEO, & Chairman, Dr. Seth Lederman for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. About Tonix Pharmaceuticals Holding Corp.Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of infectious disease, central nervous system (CNS) and immunology product candidates. Tonix’s infectious disease portfolio of product candidates includes next-generation vaccines to prevent COVID-19, an antiviral to treat COVID-19, and a potential treatment for Long COVID. The portfolio also includes a vaccine in development to prevent smallpox. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The immunology portfolio includes biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate for COVID-19, TNX-18001, is a live replicating vaccine based on Tonix’s recombinant pox vaccine (RPV) platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects to start a Phase 1 study in humans in the second half of 2022. TNX-35002 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. Finally, TNX-102 SL3 (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-COVID condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study expected to start in the first half of 2022. TNX-13004 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first quarter of 2022. 1TNX-1800 is an investigational new biologic and has not been approved for any indication. TNX-1800 is based on TNX-801, live horsepox virus vaccine for percutaneous administration, which is in development to protect against smallpox and monkeypox. TNX-801 is an investigational new biologic and has not been approved for any indication. 2TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication. 3TNX-102 SL is an investigational new drug and has not been approved for any indication. 4TNX-1300 is an investigational new biologic and has not been approved for any indication. In the NewsTonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mice Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2 Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines Tonix Pharmaceuticals Added to the Nasdaq Biotechnology Index Presentation Format:  12:00 p.m. to 1:30 p.m. - Lunch & Company Presentation Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]